

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
C12N

A2

(11) International Publication Number: WO 00/52133

(43) International Publication Date: 8 September 2000 (08.09.00)

(21) International Application Number: PCT/KR00/00173

(22) International Filing Date: 4 March 2000 (04.03.00)

(30) Priority Data:
1999/7177 4 March 1999 (04.03.99) KR
2000/10743 3 March 2000 (03.03.00) KR

(71) Applicants (for all designated States except US): KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY [KR/KR]; 52, Oun-Dong, Yusong-Ku, Taejon 305-333 (KR). DONG KOOK PHARMACEUTICAL CO. [KR/KR]; 997-8, Daechi-Dong, Kangnam-Ku, Seoul 135-280 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RHEE, Sangki [KR/KR]; GA-101, Geukdong Villa, Gwangjang-Dong, Gwangjin-K, u Seoul 143-210 (KR). CHOI, Euisung [KR/KR]; 102-507, Dasol Apt. #395-3, Goong-Dong, Yusong-Ku, Taejon 305-335 (KR). KANG, Hyunah [KR/KR]; 102-1202, Hana Apt. Shinsung-Dong, Yusong-Ku, Taejon 305-345 (KR). SOHN, Junghoon [KR/KR]; 103-506, Nuri Apt. Wolpyung-Dong, Seo-Ku, Taejon 302-280 (KR). BAE, Junghoon [KR/KR]; 302, #120-2, Shinsung-Dong, Yusong-Ku, Taejon 305-345 (KR). KIM, Moowoong

[KR/KR]; 201, Art Villa, #101-2, Oun-Dong, Yusong-Ku, Taejon 305-333 (KR). AGAPHONOV, Michael [RU/RU]; Institute of Experimental Cardiology, Cardiology Research Center, 3RD Cherepkovskaya Street 15A, Moscow, 121552 (RU). KIM, Myungkuk [KR/KR]; 102-901, Doonchonyeok Chunggu Apt, #419-1, Sungnae-3-Dong, Kangdong-Ku, Seoul 134-033 (KR).

(74) Agent: LEE, Duckrog; 2nd floor, Yeil Building, 700-19, Yorksam-Dong Kangnam-Ku, Seoul 135-080 (KR).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


Published

Without international search report and to be republished upon receipt of that report.

(54) Title: HANSENULA POLYMORPHA MUTANTS AND PROCESS FOR THE PREPARATION OF RECOMBINANT PROTEINS USING THE SAME

(57) Abstract

Disclosed are *Hansenula polymorpha* mutants useful as host cells through which various proteins can be produced as being intact at high yield and a process for preparing recombinant proteins using the host cells. Using various vectors, *Hansenula polymorpha* is made to be a mutant which is deprived of methanol assimilating ability and incapable of utilizing methanol as a carbon source. This *Hansenula polymorpha* mutant is used as a high yield host to produce recombinant proteins without continuous feeding of methanol, with the aid of an expression cassette carrying a promoter capable of inducing the expression at a low concentration of methanol. Further, the mutant is also lacking in carboxypeptidase Y, protease Y and/or carboxypeptidase α activity, so the recombinant protein of interest is not degraded at its carboxyl terminal when being expressed in the cell. Thus, intact recombinant protein can be obtained. Also, there is disclosed a pop-out technique in which a recombinant protein expression cassette is inserted into a *MOX* gene site of the mutant and is allowed to pop out therefrom, thereby utilizing the mutant as a host for general use in producing various proteins of interest.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Hansenula polymorpha MUTANTS AND PROCESS FOR THE PREPARATION
OF RECOMBINANT PROTEINS USING THE SAME

TECHNICAL FIELD

The present invention relates to *Hansenula polymorpha* mutants and a process
5 for preparing recombinant proteins using them. More particularly, the present invention
relates to *Hansenula polymorpha* mutants useful as host cells through which various
proteins can be produced as being intact at high yield and to a preparing process of
recombinant proteins using the same.

BACKGROUND ART

10 Gene recombination technology, which has been recently developed with a great
advance, allows the mass production of the proteins which are derived from higher
organisms by introducing the genes of interest into microorganisms. Largely, of interest
are the proteins that are medicinally useful because they are of high value. Demand for
proteinaceous medicines of high purity is expected to increase explosively as there
15 continue to be discovered diseases that are intractable, but curable with such
proteinaceous medicines. Thus, there are needed techniques in which functional
recombinant proteins can be produced at relatively low costs through various
microorganisms harmless to the body.

Yeast, a microorganism which performs protein expression and secretion like an
20 eucaryote, is usefully utilized as a host through which recombinant proteins derived
from higher organisms can be produced on a large scale. Typically, *Saccharomyces
cerevisiae* is used as such a host in the study on recombinant protein production using
yeast. However, the strain is now regarded unsuitable in the following aspects:
recombinant proteins are produced in low yields on account of not only the absence of a
25 strong promoter for the effective expression of exogenous proteins, but also the
instability of the plasmids introduced into the yeast upon long-term fermentation; there
is needed fed-batch fermentation when the strain is cultured at a high concentration; and

expressed exogenous proteins undergo hyperglycosylation (Romanos, et al., *Yeast*, 8: 423 (1992)). An exogenous protein expression system to overcome the above problems was developed in *Pichia pastoris*, a methanol-assimilating yeast (Sudbery et al., *Yeast*, 10: 1707 (1994); Cregg et al., *Bio/Technol.* 5: 479 (1987)). In addition, active research
5 has been directed to the development of exogenous protein expression systems using *Hansenula polymorpha*, a methanol assimilating yeast (Gellissen et al., *Bio/Technol.* 9: 291 (1991); Janowicz et al., *Yeast* 7: 431 (1991)). *Hansenula polymorpha*, which is gathering strength as a novel host cell for producing recombinant proteins, utilizes methanol as a carbon source and thus, can be mass-cultured with ease. In addition, this
10 yeast strain contains a strong promoter for several genes relevant to its methanol metabolism and allows the multicopy integration of exogenous genes into its genomic DNA so that the plasmids can be stably maintained even when it is cultured at high concentrations.

In the case that recombinant proteins are produced by use of yeast, not only is an
15 effective expression and secretion system necessary for the enhancement of the yield, but it is very important to prevent proteinases from degrading the exogenous proteins expressed and secreted. Usually, the culture of recombinant yeasts for a long period of time in a fermentation bath suffers from a problem in that proteinases secreted from the host cells to the media naturally or through cell lysis degrade the produced recombinant
20 proteins to lower the production yield of the recombinant proteins. In fact, analysis through, for example, HPLC and MS demonstrated that a substantial part of the recombinant proteins, such as human epidermal growth factor secreted from recombinant *Saccharomyces cerevisiae* (George-Nascimento et al., *Biochemistry* 27:797(1988)) and *Pichia pastoris* (Clare et al., *Gene* 105:205(1991)) cells to their
25 culture media were degraded at their carboxyl ends. It was postulated that carboxypeptidases of the host cells removed one or two amino acids from the carboxyl ends of the recombinant proteins secreted.

Corresponding to the lysosomes of higher cells, the vacuoles of *Saccharomyces cerevisiae* contain various proteinases and are responsible for proteolysis upon depletion
30 of nutrition. Particularly, carboxypeptidase Y is utilized for the carboxyl-terminal amino acid analysis by virtue of its capacity of hydrolyzing various protein substrates

and is a model protein under active and extensive study on protein sorting and targeting (Rothman et al., *Cell*, 47: 1041 (1986); Johnson et al., *Cell*, 48: 875 (1987); Valls et al., *J. Cell. Biol.*, 111: 361 (1992)). In addition, the carboxyl-terminal degradation which takes place upon the over-expression of exogenous proteins is also known to be due to
5 carboxypeptidase Y. Carboxypeptidase Y genes are reported to be cloned from *Saccharomyces cerevisiae*, *Candida albicans*, *Pichia pastoris*, and *Schizosaccharomyces pombe* (Valls et al., *Cell*, 48: 887 (1987); Mukhtar et al., *Gene*, 121: 173 (1992); Ohi et al., *Yeast*, 12: 31 (1996); Tabuchi et al., *J. Bacteriol.*, 179: 4179 (1997)).

Along with carboxypeptidase Y, *Saccharomyces cerevisiae* protease A is present
10 within vacuoles, playing a role in hydrolyzing proteins. Further, protease A takes part in the proteolytic process of vacuolar proteases, such as protease B, carboxypeptidase Y and aminopeptidase Y, as well as vacuolar hydrolases, such as RNase, alkaline phosphatase, and acid trehalase (H.B. Van Den Hasel et al., *Yeast*, 12: 1 (1996)). Particularly in the strains whose gene *PEP4* is disrupted, the activity of
15 carboxypeptidase Y is significantly reduced. Accordingly, since the activity of carboxypeptidase Y is significantly lowered in a *Hansenula polymorpha* whose *PEP4* gene is disrupted, the disruption of the *PEP4* gene on the genome can make various lyases, including carboxypeptidase Y, low in enzymatic activity. Gene *PEP4* is cloned from *Saccharomyces cerevisiae*, *Candida albicans*, and *Neurospora crassa* as disclosed
20 in several documents (Ammerer et al., *Mol. Cell. Biol.*, 6: 2490 (1986); Woolford et al., *Mol. Cell. Biol.*, 6: 25 (1986); Lott et al., *Nucleic Acids Res.*, 17: 1776 (1986); Bowman et al., Genbank Accession No U36471).

The gene *KEX1* of yeast is known to code for carboxypeptidase α that is involved in the processing of killer toxins K1 and K2 and an α -factor (mating
25 pheromone) precursor (Alexander et al., *Cell*, 50: 573 (1987)). Carboxypeptidase α is a digestive enzyme that hydrolyzes the carboxyl-terminal peptide bond in polypeptide chains. Hydrolysis had been known to occur most specifically if the carboxyl-terminal residue is a basic amino acid such as arginine or lysine. However, expression of hirudin, a thrombin inhibitor, in *Saccharomyces cerevisiae* demonstrated that the
30 specificity of carboxypeptidase α is not confined to basic amino acids, but extended further to non-basic amino acid, such as tyrosine, leucine and glutamine, at the carboxyl

end (Hinnen et al., *Gene Expression in Recombinant Microorganism*, 155:164 (1994)).

Expression systems for *Pichia pastoris* in use were usually developed by introducing in the microorganism truncated expression vectors which were then allowed to be inserted at the site of gene AOX1 or HIS4 through homologous recombination.

- 5 When an expression cassette composed of an *AOX1* promoter and a terminator is inserted to the site of gene *AOX1*, disruption occurs in the gene *AOX1*, creating an *aox1* transformant. While the normal strain produces a large quantity of AOX1 enzyme upon methanol culture, the *aox1* strain cannot produce the AOX1 enzyme any more, exhibiting a very slow growth rate (methanol utilization slow: Mut^s). Hence, this
- 10 mutant has an advantage over the AOX1 wild type (Mut⁺) in that the mutant can be grown in an even sparser oxygen atmosphere than the wild type can. There are several reports which reveal the superiority of the Mut^s recombinant strain to the Mut⁺ strain in recombinant protein production yield through the fermentation by use of the Mut^s recombinant strain and the Mut⁺ strain, indicating that the Mut^s strain is more useful for
- 15 the mass production of some recombinant protein (Cregg et al., *Bio/Technology* 5: 479 (1987); Romanos et al., *Vaccine* 9: 901 (1991)).

- In contrast, conventional expression systems for *Hansenula polymorpha* were developed by taking advantage of the phenomenon that a multicopy of an exogenous gene is tandemly introduced to non-specific sites of the genome. Accordingly, intact
- 20 expression vectors, which are not cut, but circular, are introduced into the host (Janowicz et al., *Yeast*, 7: 431 (1991); Gelalissen et al., *Trends Biotechnol.* 10: 413 (1992); Gatzke et al., *Appl. Microbiol. Biotechnol.* 43: 844 (1995)). In this case, the conventional expression systems suffer from a significant problem in that, because different expression efficiencies appear depending on the host genome sites to which the
- 25 expression vectors are inserted, there is needed the consumptive searching procedure of analyzing expression yields of numerous transformants to select the transformant which is the most productive of the recombinant protein of interest. In addition, unlike the *Pichia pastoris* expression system which is high in homologous recombination frequency, *Hansenula polymorpha* systems, even though utilizing an *MOX* promoter and
- 30 an *MOX* terminator, make exogenous genes inserted, for the most part, to non-specific sites of the host genome. Further, even when the exogenous gene is inserted to the

MOX gene site at a low frequency, the vector is incorporated as being intact, so that the *MOX* genes of the transformants are not damaged. In methanol culture media, these *MOX*⁻ transformants, to experimenters' disappointment, show poorer expression yields for the recombinant protein of interest than expected because most of the methanol fed is consumed as the substrate of the *MOX* enzyme which is of high activity (Kim et al., Biotechnol Lett. 18:417 (1996)). In the *MOX* wild types cultured in methanol, moreover, the expressed *MOX* protein amounts to as much as 30-40 % of the total expressed proteins (Guisseppin et al., Biotechnol. Bioeng. 32:577 (1988)), resulting in relatively reducing the expression efficiency of the recombinant protein of interest.

10 For *Hansenula polymorpha*, there have been not yet developed techniques by which expression cassettes inserted in the host genome can be rendered to pop out later. Thence, as indicated in the report of Hodgkins et al. (Hodgkins et al., *Yeast* 9:625), even after a desired mutant is obtained by using as a mother strain a transformant carrying an expression cassette for a particular recombinant protein, the mutant, which is obtained

15 under difficulties, cannot be used as a general host to express various recombinant proteins because of the incapability of popping out the preexisting expression vector from the host genome and thus of introducing a new expression cassette into the host genome.

DISCLOSURE OF THE INVENTION

20 In order to produce whole recombinant proteins in *Hansenula polymorpha*, there are developed *Hansenula polymorpha* mutant strains that are deficient in proteases. To begin with, the genes *PRC1*, *KEX1* and *PEP4* which code for carboxypeptidase Y, carboxypeptidase α and protease A, respectively are cloned. By taking advantage of these cloned genes, a carboxypeptidase Y-deficient mutant strain, a carboxypeptidase α -

25 deficient mutant strain, a protease A-deficient mutant, and multi-phenotype deficient mutant strains are developed. The exogenous proteins produced from these mutant strains show a remarkable decrease in the amino acid degradation in their carboxyl terminal regions. In the invention, *Saccharomyces cerevisiae* genes are utilized to clone the genes of interest from *Hansenula polymorpha*. The *Saccharomyces cerevisiae*

carboxypeptidase Y gene (*PRC1*) is obtained by PCR and used as a probe to detect the *Hansenula polymorpha PRC1* by Southern blotting. The genome of *Hansenula polymorpha* DL-1 is digested with various restriction enzymes and repetitively subjected to Southern blotting, so as to determine the base sequence of the *Hansenula polymorpha* *PRC1*. This procedure can be applied to determine the base sequence of the gene *PEP4* coding for the protease A of *Hansenula polymorpha* DL-1. For the cloning of *Hansenula polymorpha KEX1* gene, primers are synthesized on the basis of a high homology region among strains and used to amplify a portion of the *KEX1* gene by PCR with the *Hansenula polymorpha* genome serving as a template. The PCR product is used as a probe for Southern blotting to clone the whole *KEX1* gene of *Hansenula polymorpha*.

A *Hansenula polymorpha LEU2* gene is inserted into plasmids pHDY2 and pHDP4 to construct plasmid pHYL and pHPL, respectively. With the constructed plasmids pHYL and pHPL, *Hansenula polymorpha* UR2 is transformed into a carboxypeptidase Y mutant and a protease A mutant, respectively. Investigation of the carboxypeptidase activity of these mutants and Southern blotting analysis identify the disruption of the *Hansenula polymorpha PRC1* and *PEP4* genes.

In order to disrupt the *KEX1* gene of *Hansenula polymorpha* DL1 strain, plasmid pKUZ is constructed by inserting a *Hansenula polymorpha URA3* gene pop-out cassette into plasmid pKH3.9 and used to transform the *Hansenula polymorpha* DL1 strain into a carboxypeptidase α mutant strain. Selection is made on a *Hansenula polymorpha URA3* gene pop-out strain whose genome, together with the genome of the wild type, is then subjected to Southern blotting to identify the disruption of the *KEX1* gene. In addition, the genes *PRC1* and *PEP4* of *Hansenula polymorpha* DL1 strain are both disrupted. In this regard, a *Hansenula polymorpha URA3* gene pop-out cassette is inserted into plasmids pHDY2 and pHDP4 to construct plasmids pHTUZ and pHPUZ, respectively. As in the *KEX1* gene disruption, transformation and popping out are repeated to prepare a protease A/carboxypeptidase α mutant, a protease A/carboxypeptidase Y mutant, a carboxypeptidase α /carboxypeptidase Y mutant, and a protease A/carboxypeptidase α /carboxypeptidase Y mutant.

In the invention, there is also constructed a vector which can disrupt a *MOX*.

gene coding for methanol oxidase, a first enzyme in the methanol metabolism of methanol-assimilating *Hansenula polymorpha*, and a *TRP3* gene adjacent to the *MOX* gene, at once. This vector is used to prepare a novel mutant DLT2 whose *MOX* gene is disrupted. The novel mutant DLT2 can serve as a host through which recombinant
5 proteins of interest can be produced at high yield without continuous feeding of methanol, with the aid of an expression cassette carrying a promoter capable of inducing the expression at a low concentration of methanol. Further, there is developed a pop-out technique in which a recombinant protein expression cassette is inserted into a *MOX* gene site of the mutant and is allowed to pop out therefrom, thereby utilizing the mutant
10 as a host for general use in producing various proteins of interest.

Therefore, it is an object of the present invention to provide gene base sequences coding for carboxypeptidase Y, carboxypeptidase α and protease A, respectively, derived from *Hansenula polymorpha*.

It is another object of the present invention to provide mutant strains deficient in
15 carboxypeptidase Y, carboxypeptidase α , protease A and combinations thereof, which are transformed from *Hansenula polymorpha* by use of vectors which contain a disrupted *PRC1* gene coding for carboxypeptidase Y, a disrupted *KEX1* gene coding for carboxypeptidase α , a disrupted *PEP4* gene coding for protease A, and combinations thereof.

20 It is a further object of the present invention to provide a process for producing recombinant proteins, in which the protease mutant strains are utilized as host cells to produce the recombinant proteins without degradation at carboxyl terminal.

It is still a further object of the present invention to provide a process for producing recombinant proteins at high yield, in which a *Hansenula polymorpha*
25 mutant, deprived of methanol assimilating ability and incapable of utilizing methanol as a carbon source, is used as a high yield host to produce recombinant proteins without continuous feeding of methanol, with the aid of an expression cassette carrying a promoter capable of inducing the expression at a low concentration of methanol.

It is still another object of the present invention to provide a pop-out technique
30 in which a recombinant protein expression cassette is inserted into a *MOX* gene site of the mutant and is allowed to pop out therefrom, thereby utilizing the mutant as a host

for general use in producing various proteins of interest.

BRIEF DESCRIPTION OF THE DRAWINGS

The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken
5 in conjunction with the accompanying drawings, in which:

Fig. 1 is a restriction map of a *Hansenula polymorpha* *PRC1* gene;

Fig. 2 is a restriction map of a *Hansenula polymorpha* *PEP4* gene;

Fig. 3 is a restriction map of a *Hansenula polymorpha* *KEX1* gene;

Fig. 4 shows the construction of a plasmid comprising a disrupted *Hansenula*
10 *polymorpha* *PRC1* gene by a *LEU2* gene, which plasmid is useful to disrupt the *PRC1* gene on the host genome, and its restriction map;

Fig. 5 shows the construction of a plasmid comprising a disrupted *Hansenula*
polymorpha *PRC1* gene by a *URA3* gene, which plasmid is useful to disrupt the *PRC1* gene on the host genome, and its restriction map;

15 Fig. 6 shows the construction of a plasmid comprising a disrupted *Hansenula*
polymorpha *PEP4* gene by a *LEU2* gene, which plasmid is useful to disrupt the *PEP4* gene on the host genome, and its restriction map;

Fig. 7 shows the construction of a plasmid comprising a disrupted *Hansenula*
polymorpha *PEP4* gene by a *URA3* gene, which plasmid is useful to disrupt the *PEP4*
20 gene on the host genome, and its restriction map;

Fig. 8 shows the construction of a plasmid comprising a disrupted *Hansenula*
polymorpha *KEX1* gene by a *URA3* gene, which plasmid is useful to disrupt the *KEX1* gene on the host genome, and its restriction map;

Fig. 9 shows the results of Southern blotting for confirming the disruption of
25 genes of interest;

Fig. 10 shows the construction of vector pMLT-delta for disrupting *MOX-TRP3* genes and its restriction map;

Fig. 11 shows the change on the genome upon the preparation of Δ *mox* mutant DLT2 with the vector pMLT-delta;

Fig. 12 shows *MOX* wild type and Δmox mutant DLT2 strain which are grown on various media containing dextrose or methanol as a main carbon source;

Fig. 13 shows the feasibility of the transformation from wild type to a mutant and *vice versa*: introduction of a recombinant protein expression cassette into a *MOX* gene site of the Δmox mutant DLT2 (A); Popping out of the expression cassette from the transformed DLT2 (B); and Returning to *MOX* wild type (C);

Fig. 14 is a histogram showing the expression of albumin in the *MOX* DL-1L and the Δmox mutant DLT2; and

Fig. 15 shows the process to develop super-secretion mutant strains as the general host strains for the production of recombinant proteins using the pop-out technique.

BEST MODES FOR CARRYING OUT THE INVENTION

A *Sacchromyces cerevisiae* carboxypeptidase Y gene (*PRC1*) is amplified by PCR. This PCR product is used as a probe in detecting a corresponding *Hansenula polymorpha* gene (*PRC1*) through Southern blotting. First, the genome of *Hansenula polymorpha* DL-1 is treated with restriction enzymes and hybridized with the probe. A DNA band is detected from a 3 kb *Pst*I DNA fragment which is, then, inserted into a plasmid for preparing a DNA library. After extensive Southern blotting processes, a plasmid carrying a *Hansenula polymorpha PRC1* gene was selected. After the DNA fragment is reduced into a 2.2 kb *Xho*I/*Pst*I fragment which is then used to construct plasmid pHDY2. The base sequence of the gene is read as given in Sequence 1.

Based on a well known *Sacchromyces cerevisiae PEP4* gene, a set of two primers is synthesized. After being amplified by PCR with the aid of the primers, the *Sacchromyces cerevisiae PEP4* gene fragment is used as a probe for Southern blotting. First, the genome of *Hansenula polymorpha* DL-1 is treated with restriction enzymes and hybridized with the probe. A DNA band is detected from a 8 kb *Bam*HI DNA fragment which is, then, inserted into a plasmid for preparing a DNA library. After extensive Southern blotting processes, a plasmid carrying a *Hansenula polymorpha PEP4* gene was selected.

Well-known amino acid sequences of carboxypeptidase α of many strains are analyzed to select high homology regions. On the basis of the amino acid sequences of the high homology regions, primers are designed. A PCR using the primers resulted in the amplification of a *KEX1* DNA fragment 306 bp long, from the *Hansenula polymorpha* DL-1 genome. This PCR product is used as a probe in detecting a whole *Hansenula polymorpha* gene *KEX1* through Southern blotting. First, the genome of *Hansenula polymorpha* DL-1 is treated with restriction enzymes and hybridized with the probe. A DNA band is detected from a 4.5 kb *HindIII* DNA fragment which is, then, inserted into a plasmid for preparing a DNA library. After extensive Southern blotting processes, a plasmid carrying a *Hansenula polymorpha KEX1* gene was selected. After the DNA fragment is reduced into a 3.9 kb *EcoRI/HindIII* fragment which is then used to construct plasmid pKH3.9. The base sequence of the gene is read as given in Sequence 3.

The cloned carboxypeptidase Y gene (*PRC1*) and protease A gene (*PEP4*) are utilized to disrupt their corresponding genes on the genome of *Hansenula polymorpha* DL-1. To this end, a *Hansenula polymorpha LEU2* gene is inserted into plasmids pHDY2 and pHDP4 to construct pHYL and pHPL, respectively. Using these plasmids, a *Hansenula polymorpha* UR2 strain (*leu2*, *hEGF*, *PRC1*, *PEP4*, *KEX1*) is transformed into a carboxypeptidase mutant strain (*hEGF*, *prc1::LEU2*, *PEP4*, *KEX1*) and a protease mutant strain (*hEGF*, *pep4::LEU2*, *PRC1*, *KEX1*), respectively. The disruption of the genes of interest can be confirmed by analyzing the resulting mutants for the activity of the carboxypeptidase Y and by genomic Southern hybridization between the mutants and the wild type.

For the multi-disruption of *KEX1*, *PEP4* and *PRC1* genes, a *Hansenula polymorpha URA3* gene pop-out cassette is introduced into plasmid pKH3.9, pHDY, pHDP4 to construct plasmids pKUZ, pHYUZ, and pHPUZ, respectively. With the plasmid pKUZ, a *Hansenula polymorpha* DL1 strain (*leu2*, *ura3*, *KEX1*, *PEP4*, *PRC1*) is transformed into a carboxypeptidase α mutant strain (*leu2*, *kex1::URA3*, *PEP4*, *PRC1*), followed by popping the *URA3* gene out. Likewise, the plasmids pHYUZ and pHPUZ are used to prepare a carboxypeptidase Y mutant strain and a protease A mutant strain, respectively. The disruption of the genes of interest can be confirmed by

genomic Southern hybridization between the mutants and the wild type.

The recombinant protein of interest, for example, hEGF is expressed in the carboxypeptidase Y/protease A mutant strain. This protein can be obtained with ease by attaching a signal peptide to the protein. In this case, the recombinant protein can be
5 obtained only by centrifugation of the cell culture. HPLC analysis is useful to determine whether the recombinant protein is degraded at its carboxyl terminal.

Also, in an embodiment of the present invention, there is provided a process for producing recombinant proteins by use of a *Hansenula polymorpha* mutant strain whose methanol oxidase gene (*MOX*) is disrupted. In the process, a vector for disrupting the
10 *MOX* gene and its neighboring *TRP3* gene on the genome of *Hansenula polymorpha* is constructed and introduced into the host to prepare a Δmox mutant. In this mutant, an recombinant protein expression cassette can be inserted into or popped out from the genome. Culturing the Δmox mutant harboring a gene of interest in a methanol medium results in producing the corresponding recombinant protein at high yield. As a vector
15 for disrupting the *MOX* and *TRP3* genes on the genome of *Hansenula polymorpha*, at once, pMLT-delta was developed and deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology (KRIBB) under the accession No. KCTC 0727BP on Feb. 10, 2000. Using this vector, a *Hansenula polymorpha* mutant DLT2 whose genomic *MOX* and *TRP3* genes are disrupted was also
20 developed and deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology under the accession number of KCTC 0728BP on February 10, 2000. The novel mutant DLT2 can serve as a host through which recombinant proteins of interest can be produced at high yield without continuous feeding of methanol, with the aid of an expression cassette carrying a promoter capable
25 of inducing the expression at a low concentration of methanol.

Further, in another embodiment of the present invention, there is provided a pop-out technique in which a recombinant protein expression cassette is inserted into a *MOX* gene site of the mutant and is allowed to pop out therefrom, thereby utilizing the mutant as a host for general use in producing various proteins of interest.

30 A better understanding of the present invention may be obtained in light of the following examples which are set forth to illustrate, but are not to be construed to limit

the present invention.

EXAMPLE I

Preparation of Protease Gene-Disrupted Mutant of *Hansenula polymorpha*

Experiment 1: Isolation of Genes Carboxypeptidase Y-Encoding *PRC1*, Protease A- 5 Encoding *PEP4*, and Carboxypeptidase α -Encoding *KEX1*

First step: Construction of Probes for Cloning *Hansenula polymorpha* Genes *PRC1*, *PEP4* and *KEX1*

In order to obtain a *Saccharomyces cerevisiae* *PRC1* gene, there were used the following primers:

10 Primer C1: 5'-ATG AAA GCA TTC ACC AG-3'

Primer C2: 5'-TTA TAA GGA GAA ACC AC-3'

With the aid of the primers C1 and C2, 25 cycles of PCR, each consisting of a denaturing step at 94 °C for 30 sec, an annealing step at 55 °C for 30 sec and an extending step at 72 °C for 2 min, resulted in the acquisition of a *Sacchchromyces*
15 *cerevisiae* *PRC1* gene 1.6 kb long while the genomic DNA of *Sacchchromyces cerevisiae* served as a template for the enzyme. Using a DIG-labelling and detection kit, commercially available from Boehringer Mannheim, the PCR product was labeled according to the indications of the kit manual to give a probe for cloning a *PRC1* gene of *Hansenula polymorpha*.

20 Synthesized for the amplification of a *Sacchchromyces cerevisiae* *PEP4* gene were the following primers:

Primer P1: 5'-ATG TTC AGC TTG AAA GC-3'

Primer P2: 5'-TCA AAT TCG TTT GGC C-3'

The *Sacchchromyces cerevisiae* *PEP4* gene 1.22 kb long was obtained from the
25 *Sacchchromyces cerevisiae* genomic DNA through 25 cycles of PCR, each consisting of a denaturing step at 94 °C for 30 sec, an annealing step at 55 °C for 30 sec and an extending step at 72 °C for 2 min. This *PEP4* gene was labeled in the same manner as in the above *Hansenula polymorpha* *PRC1* gene, so as to give a probe for cloning a

PEP4 gene of *Hansenula polymorpha*.

As for a probe for detecting a *Hansenula polymorpha KEX1* gene, it was obtained by PCR using the following primers:

Primer K1: 5'-TGG YTS AAC GGH CCW GGH TGY TCB TCB-3'

5 Primer K2: 5'-WGG RAT GTA YTG WCC RGC GTA VGA CTC DCC-3'

In this regard, five cycles of a PCR, each consisting of a denaturing step at 94 °C for 30 sec, an annealing step at 50 °C for 30 sec and an extending step at 72 °C for 30 sec was conducted, followed by performing 20 cycles of a PCR under the heat condition consisting of a denaturing step at 94 °C for 30 sec, an annealing step at 55 °C for 30
10 sec and an extending step at 72 °C for 30 min to amplify a *Hansenula polymorpha KEX1* DNA segment 306 bp. This DNA segment was labeled in the same manner as in the above to prepare a probe for cloning a *Hansenula polymorpha PRC1* gene.

Second step: Isolation of Genomic DNA from *Hansenula polymorpha* DL1

From the *Hansenula polymorpha* DL1 cultured in a YEPD medium (peptone 2%,
15 Yeast extract 1%, glucose 2%), genomic DNA was isolated according to the Johnstone's method (Yeast Genetics, molecular aspects, pp. 107-123, IRL Press, 1988).

Third step: Construction of Plasmid pHDY2

In order to detect a *PRC1* gene from the genomic DNA of *Hansenula polymorpha*, Southern blotting was conducted with the probe prepared in the first step.
20 First, after six aliquots of the genomic DNA obtained in the second step were treated with restriction enzymes *Bam*HI, *Eco*RI, *Eco*RV, *Hind*III, *Pst*I, and *Sal*I, respectively, the resulting DNA fragments were fractionated on a 0.9% agarose gel by electrophoresis. The separated DNA molecules were transferred to a Nytran membrane (Schleicher & Schuell) by blotting, followed by exposing the membrane to the labeled
25 probe under conditions favoring hybridization. For this hybridization, a hybrid buffer (5X SSC, 0.1% N-lauryl sarcosine, 0.02% SDS, 2% blocking agent, 30% formamide) was used at 42 °C for 6 hours as indicated in the product manual of Boehringer Mannheim. The membrane was added with an alkaline phosphatase-conjugated antibody and then with BCIP and X-phosphate for color reaction. A band that was dyed

blue was observed in a DNA fragment which was cut into a length of about 3 kb by restriction enzyme *Pst*I.

Next, the DNA fragment was isolated from the position at which the blue band appeared, and ligated to plasmid pBluescript KSII⁺ with which *E. coli* DH5 α was transformed to prepare a DNA library. This DNA library was subjected repetitively to Southern blotting to select a plasmid carrying the *PRC1* gene, called plasmid pHDY1. Double digestion with restriction enzymes *Xho*I/*Pst*I reduced the DNA fragment from about 3 kb to about 2.2 kb. The plasmid harboring the *Xho*I/*Pst*I DNA fragment, was called pHDY2. It was deposited in the Korean Collection for Type Culture(KCTC), placed in Korea Research Institute of Bioscience and Biotechnology(KRIBB), #52, Oundong, Yusong-ku, Taejon 305-333, Republic of Korea, on the date of Feb. 18, 2000 and it was accepted under the accession number of KCTC 0732BP. The restriction site mapping and base sequencing of the *Hansenula polymorpha* DL1 *PRC1* gene was conducted as illustrated in Fig. 1. The base sequence of the *PRC1* gene is given in Sequence 1. This DNA sequence was registered as U67174 with GenBank on Aug. 17, 1996. Analysis of the base sequence revealed that the *Hansenula polymorpha* DL1 *PRC1* gene is 1,626 bp long with no introns and shows 54% homology to the base sequence of a *Saccharomyces cerevisiae* *PRC1* gene. When being deduced from Sequence 1, the amino acid sequence of the *Hansenula polymorpha* DL1 *PRC1* gene exhibits 50 % homology to the carboxypeptidase Y of *Saccharomyces cerevisiae*. In addition, high homology can be found in the region around of 263rd amino acid residue, which is identified to be a serine acting as a catalytic group within an active site of serine protease.

Fourth step: Construction of Plasmid pHDP4

In order to obtain a *PEP4* gene from the genomic DNA of *Hansenula polymorpha*, Southern blotting was conducted with the probe prepared in the first step. First, after six aliquots of the genomic DNA obtained in the second step were treated with restriction enzymes *Bam*HI, *Eco*RI, *Eco*RV, *Hind*III, *Pst*I, and *Sal*I, respectively, the resulting DNA fragments were fractionated on a 0.9% agarose gel by electrophoresis. The separated DNA molecules were transferred to a Nytran membrane

(Schleicher & Schuell) by blotting, followed by exposing the membrane to the labeled probe under conditions favoring hybridization. The hybridization was conducted in the same manner as in the third step. A band that was dyed blue was observed in a DNA fragment which was cut into a length of about 8 kb by restriction enzyme *Bam*HI. Next, the DNA fragment was isolated from the position at which the blue band appeared, and used to prepare a DNA library in the same manner as in the third step. The DNA library was subjected repetitively to Southern blotting to select a plasmid carrying the *PRC1* gene, called plasmid pHDP3. Double digestion with restriction enzymes *Sac*I/*Hind*III reduced the DNA fragment from about 8 kb to about 2.0 kb. The plasmid harboring the *Sac*I/*Hind*III DNA fragment, was called pHDY4. It was deposited in the Korean Collection for Type Culture(KCTC), placed in Korea Research Institute of Bioscience and Biotechnology(KRIBB), #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on the date of Feb. 18, 2000 and it was accepted under the accession number of KCTC 0733BP. The restriction site mapping and base sequencing of the *Hansenula polymorpha* DL1 *PEP4* gene was conducted as illustrated in Fig. 2. The base sequence of the *PEP4* gene is given in Sequence 2. This DNA sequence was registered as U67173 with GenBank on Aug. 17, 1996. Analysis of the base sequence revealed that the *Hansenula polymorpha* DL1 *PEP4* gene is 1,242 bp long with no introns and shows 52.4% homology to the base sequence of a *Saccharomyces cerevisiae* *PRC1* gene. When being deduced from Sequence 2, the amino acid sequence of the *Hansenula polymorpha* DL1 *PEP4* gene exhibits 50 % homology to the protease A of *Saccharomyces cerevisiae*. In addition, high homology can be found in the 117th amino acid residue, which is identified to be an aspartic acid acting as a catalytic group within an active site of aspartyl protease.

25 Fifth step: Construction of Plasmid pKH3.9

In order to obtain a *KEX1* gene from the genomic DNA of *Hansenula polymorpha*, Southern blotting was conducted with the probe prepared in the first step. First, after six aliquots of the genomic DNA obtained in the second step were treated with restriction enzymes *Bam*HI, *Eco*RI, *Eco*RV, *Hind*III, *Pst*I, and *Sal*I, respectively, the resulting DNA fragments were subjected to electrophoresis on a 0.9% agarose gel.

The separated DNA molecules were transferred to a Nytran membrane (Schleicher & Schuell) by blotting, followed by exposing the membrane to the labeled probe under conditions favoring hybridization. The hybridization was conducted in the same manner as in the third step, but using a modified hybrid solution (5X SSC, 0.1% N-lauryl sarcosine, 0.02% SDS, 2% blocking agent, 50% formamide). A band that was dyed blue was observed in a DNA fragment which was cut into a length of about 4.5 kb by restriction enzyme *HindIII*.

Next, the DNA fragment was isolated from the position at which the blue band appeared, and used to prepare a DNA library as in the third step. The DNA library was subjected repetitively to Southern blotting to select a plasmid carrying the *PRC1* gene, called plasmid pKH4.5. The plasmid pKH4.5 was deposited in the Korean Collection for Type Culture(KCTC), placed in Korea Research Institute of Bioscience and Biotechnology(KRIBB), #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on the date of Feb. 18, 2000 and it was accepted under the accession number of KCTC 0731BP. Double digestion with restriction enzymes *EcoRI/HindIII* reduced the DNA fragment from about 4.5 kb to about 3.9 kb. The plasmid harboring the *EcoRI/HindIII* DNA fragment, was called pKH3.9. The restriction site mapping and base sequencing of the *Hansenula polymorpha* DL1 *PRC1* gene was conducted as illustrated in Fig. 3. The base sequence of the *PRC1* gene is given in Sequence 3. This DNA sequence was registered as AF090325 with GenBank on Sep. 4, 1998. Analysis of the base sequence revealed that the *Hansenula polymorpha* DL1 *KEX1* gene is 1,833 bp long with no introns. When being deduced from Sequence 2, the amino acid sequence of the *Hansenula polymorpha* DL1 *KEX1* gene exhibits as low as 20 % homology to the carboxypeptidase α of *Sacchromyces cerevisiae*. However, in the 176th amino acid residue, which is identified to be a serine acting as a catalytic group within an active site of serine protease, there is found high homology to carboxypeptidase α as well as carboxypeptidase Y. Amino acid analysis according to Von Heijne's method (Von Heijne, *J. Mol. Biol.*, 173: 243 (1984)) divulged the presence of a signal peptide consisting of 18 amino acid residues.

30 Experiment 2: Preparation of Mutant Strains with Disrupted Plasmids

First step: Construction of Disrupted Plasmid pHYL

A *LEU2* gene of *Hansenula polymorpha* was inserted into the *PRC1* gene cloned in the plasmid pHDY2 constructed in the Experiment 1, as shown in Fig. 4. To this end, a 1.2 kb *LEU2* gene fragment of *Hansenula polymorpha* was first obtained by the
5 excision with restriction enzymes *EcoRI* and *BamHI*, and made blunt at its opposite ends through Klenow treatment. This blunt-ended *LEU2* gene fragment was inserted to the *SmaI* site of the *PRC1* gene on the plasmid pHDY2 to construct plasmid pHYL, which was used to disrupt the *PRC1* gene coding for carboxypeptidase Y on the genome of *Hansenula polymorpha* DL-1, later.

10 Second step: Construction of Disrupted Plasmid pHPL

A *LEU2* gene of *Hansenula polymorpha* was inserted into the *PEP4* gene cloned in the plasmid pHDP4 constructed in the Experiment 1, as shown in Fig. 6. To this end, a 1.05 kb DNA fragment was removed from the *PEP4* gene in the plasmid pHDP4 by use of restriction enzyme *EcoRV* while a 1.2 kb *LEU2* gene fragment of *Hansenula*
15 *polymorpha* obtained by the excision with restriction enzymes *EcoRI* and *BamHI* was made blunt at its opposite ends through Klenow treatment. Then, this blunt-ended *LEU2* gene fragment was inserted into the truncated plasmid pHDP4, replacing the removed portion of the *PEP4* gene, so as to give plasmid pHPL, which was used to disrupt the *PEP4* gene coding for protease A on the genome of *Hansenula polymorpha*
20 DL-1, later.

Third step: Construction of Disrupted Plasmids pKUZ, pHYUZ, and pHPUZ

In order to disrupt the cloned *KEX1* gene of *Hansenula polymorpha* DL-1, there was constructed a pop-out cassette which was structured to allow a *Hansenula*
polymorpha URA3 gene to be repetitively used as a selective marker, as shown in Fig.
25 8. In this regard, a *BamHI/PvuII LacZ* DNA fragment of 211 bp obtained from plasmid pUC19 was linked to each of the opposite ends of a *Hansenula polymorpha URA3* gene of 1,323 bp in the same direction to prepare pop-out plasmid pLacUR3.

Separately, the plasmid pKH3.9 was digested with restriction enzyme *SmaI* and

EcoRI to remove a 1,148 bp fragment comprising the promoter and a portion of the coding region. The pLacUR3 was cut with restriction enzymes *PvuII* and *EcoRI* to give a 1,735 bp *Hansenula polymorpha URA3* gene fragment comprising two direct repeats of the 211 bp *LacZ* gene. This *Hansenula polymorpha URA3* gene was linked to the
5 truncated plasmid pKH3.9, replacing the 1,148 bp fragment, so as to construct plasmid pKUZ.

As in the construction of the plasmid pKUZ, the pop-out plasmid pLacUR3 was treated with restriction enzymes *PvuII* and *EcoRI* to give a 1,735 bp *Hansenula polymorpha URA3* gene fragment, which was then inserted into the plasmid pHDY2,
10 replacing a 1,055 bp fragment comprising a portion of the coding region, which had been removed from the plasmid pHDY2 through the treatment with *SmaI* and *EcoRI*, as shown in Fig. 5. The resulting plasmid was called pHYUZ.

Likewise, the cloned *PEP4* gene of *Hansenula polymorpha* DL-1 in pHDP4 was disrupted by use of the pop-out cassette. A *Hansenula polymorpha URA3* gene
15 fragment 1,800 bp long, which was obtained by treating the pop-out plasmid pLacUR3 with restriction enzymes *PvuII* and *SalI*, was inserted into the plasmid pHDP4, replacing a 303 bp fragment comprising a portion of the coding region, which had been excised from the plasmid pHDP4 by *XhoI* and *EcoRV*, as shown in Fig. 7. The resulting plasmid was called pHPUZ.

20 Fourth step: Transformation with disrupted plasmid

Using the plasmid pKUZ constructed above, a *Hansenula polymorpha* DL1 strain (*leu2*, *ura3*, *KEX1*, *PEP4*, *PRC1*) was transformed into a carboxypeptidase α mutant strain (*leu2*, *kex1::URA3*, *PEP4*, *PRC1*) which was then cultured for more than 72 hours on a minimal solid medium (0.7% yeast base deficient in amino acids (YNB),
25 2% glucose, uracil 50 μ g/mL, leucine 50 μ g/mL, 2% agar) supplemented with 0.1% 5-fluoroorotic acid so as to select a *URA3* gene pop-out strain of *Hansenula polymorpha* (*leu2*, *ura3*, *kex1::LacZ*, *PEP4*, *PRC1*). The *Hansenula polymorpha* DL1/ Δ *kex1* was deposited in the Korean Collection for Type Culture (KCTC), placed in Korea Research Institute of Bioscience and Biotechnology (KRIBB), #52, Oun-dong, Yusong-ku, Taejon
30 305-333, Republic of Korea, on the date of February 18, 2000 and it was accepted under

the accession number of KCTC 0736BP. This mutant strain was again transformed with the plasmid pHYUZ into a carboxypeptidase α /carboxypeptidase Y mutant strain (*leu2*, *kex1::LacZ*, *prc1::URA3*, *PEP4*). Culturing the carboxypeptidase α /carboxypeptidase Y mutant strain on a minimal solid medium supplemented with 0.1% 5-fluoroorotic acid
5 afforded the selection of a *URA3* gene pop-out strain (*leu2*, *ura3*, *kex1::LacZ*, *prc1::LacZ*, *PEP4*). Through the same transformation and culturing as in the above, the *URA3* gene pop-out, carboxypeptidase α /carboxypeptidase Y mutant strain (*leu2*, *ura3*, *kex1::LacZ*, *prc1::LacZ*, *PEP4*) was converted into a *URA3* gene pop-out, carboxypeptidase α /carboxypeptidase Y/protease A mutant strain (*leu2*, *ura3*,
10 *kex1::LacZ*, *prc1::LacZ*, *pep4::lacZ*) with the aid of the plasmid pHPUZ.

Likewise, a combination of plasmids pHYUZ and pHPUZ was used to prepare a carboxypeptidase Y/protease A mutant strain (*leu2*, *ura3*, *prc1::LacZ*, *pep4::lacZ*, *KEX1*) while use of a combination of plasmids pKUZ and pHPUZ resulted in the preparation of a carboxypeptidase α /protease A mutant strain (*leu2*, *ura3*, *kex1::LacZ*,
15 *pep4::lacZ*, *PRC1*).

Transformation of *Hansenula polymorpha* was conducted according to a lithium acetate method. A *Hansenula polymorpha* UR2 (*leu2*) strain which was highly productive of hEGF was cultured in a YEPD broth (peptone 2%, yeast extract 1%, glucose 2%) to the extent of OD6000=0.5. After being harvested, the cells were washed
20 with an LiTE solution (0.1M Tris-Cl, pH 8.0, 10mM EDTA, 10mM LiAc, pH 7.5) and then, resuspended in 0.01 volume of LiTE solution to give competent cells. To 100 μ l of the competent cells were added 0.5 g of a plasmid of interest, 10 μ g of salmon sperm DNA, which was to serve as a carrier DNA, and 0.6 mL of a PEC/LiAc solution (40% PEG 4000, 0.1 M Tris-Cl, pH 8.0, 10 mM EDTA, 10 mM LiAc, pH 7.5). The resulting
25 cell mixture was allowed to stand for 30 min at 30 °C, added with 70 μ l of DMSO, allowed to stand again at 42 °C for 15 min, and quenched in ice. After being harvested, the cells were cultured on a minimal solid medium (0.67% yeast base deficient in amino acids, 2% glucose, 2% agar) at 37 °C for 72 hours. For use in transformation, the plasmid pHYL was linearized by use of restriction enzymes *HindIII*/*NcoI*, the plasmid
30 pKUZ by use of *XhoI*, the plasmid pHYUZ by use of *XhoI*/*PstI*, and the plasmid pHPUZ by use of *SpeI*/*SnaBI*.

Experiment 3: Measurement of Carboxypeptidase Y Mutant Strain and Protease A Mutant Strain for Carboxypeptidase Y Activity and Analysis of hEGF Produced from the Strains

First step: Measurement of Carboxypeptidase Y Mutant Strain and Protease A Mutant
5 Strain for Carboxypeptidase Y Activity

A 2.5 mg/mL solution of N-benzoyl-L-tyrosine-p-nitroanilide in dimethylformamide and 0.1 M Tris-HCl (pH 7.5) were mixed in the volume ratio of 1:4 and 0.2 mL of the resulting solution was allotted to each well of a 96 well microtiter plate. The transformants obtained in Experiment 2 were inoculated into the wells and
10 incubated at 37 °C for 16 hours. Based on the fact that a cell culture became yellow by the enzymatic action of active carboxypeptidase while a cell culture without active carboxypeptidase or with inactive carboxypeptidase remained colorless, absorbance at 450 nm was measured to select strains whose *PRC1* gene was effectively disrupted. In addition, because the processing of carboxypeptidase Y was inhibited in protease A
15 mutant strains, measurement of the activity of carboxypeptidase Y was utilized to select *PEP4* gene-disrupted strains.

The results are given in Table 1, below. As shown in Table 1, nearly no activity of carboxypeptidase was detected in the carboxypeptidase Y mutant strain while the activity of carboxypeptidase Y was reduced by more than 60% in the protease A mutant
20 strain. By these results, the genes *PRC1* and *PEP4* cloned in the invention were identified as coding for the carboxypeptidase Y and the protease A of *Hansenula polymorpha*, respectively. In addition, it was demonstrated that remarkable reduction was brought about in the activity of carboxypeptidase in the mutant strains which were disrupted in *PRC1* and/or *PEP4* gene. The transformed *Hansenula polymorpha*
25 DL1/ Δ cpy and *Hansenula polymorpha* DL1/ Δ pep4 were deposited in the Korean Collection for Type Culture(KCTC), placed in Korea Research Institute of Bioscience and Biotechnology(KRIBB), #52, Oun-dong, Yusong-ku, Taejon 305-333, Republic of Korea, on the date of Feb. 18, 2000 and it were accepted under the accession number of KCTC 0735BP and KCTC 0734BP, respectively.

TABLE 1

Activity of Carboxypeptidase in Carboxypeptidase Y Mutant Strain

Strains	Genotype	Carboxypeptidase A Activity (Abs)
<i>Hansenula polymorpha</i> UR2	<i>leu2, PEP4, PRC1, hEGF</i>	2.97
REP4 Mutant	<i>pep4::LEU2, PRC1, hEGF</i>	1.00
PRC1 Mutant	<i>prc1::LEU2, PEP4, hEGF</i>	0.10

Second step: Confirmation of the Disruption By Southern Blotting

10 Southern blotting was conducted to confirm the disruption of the *Hansenula polymorpha* genes *PRC1* and *PEP4* with the *Hansenula polymorpha* gene *LEU2* and the disruption of the *Hansenula polymorpha* gene *KEX1* with the *Hansenula polymorpha* gene *URA3*. Each of the transformants selected in the fourth step of Experiment 3 was inoculated in a YEPD medium and cultured at 37 °C for 18-20 hours with shaking.

15 After being harvested by centrifugation, the cells were suspended in 30 μ l of an STES solution (0.5M NaCl, 0.01M EDTA, 1% SDD in 0.2M Tris-Cl, pH 7.6) in 1.5 mL tubes, added with 0.8 volumes of glass beads which were 0.4 mm in diameter, and vortexed for 5 min. Then, each tube was added with 200 μ l of a TE buffer (1 mM EDTA in 10 mM Tris-Cl, pH 8.0) and 200 μ l of phenol/chloroform/isoamylalcohol (25:24:1) and

20 vortexed for 2 min before being centrifuged at 12,000 rpm. To the supernatant was added 2.5 volumes of ethanol so as to precipitate the genomic DNA. 2-3 μ g of the genome DNA was dissolved in deionized water.

This DNA solution was treated with restriction enzyme. Restriction enzyme *EcoRI* was used for the genomic DNA of the *PRC1* gene-disrupted strain, restriction

25 enzyme *EcoRV* for the genomic DNA of the *PEP4* gene-disrupted strain, and restriction enzyme *XhoI* for the genomic DNA of the *KEX1* gene-disrupted strain. The DNA molecules cut with the restriction enzymes were fractionated on 0.8% agarose gel by electrophoresis. The genes *PRC1*, *PEP4*, and *KEX1* shown respectively in Figs. 1, 2 and 3 were used as probes for Southern blotting and the results are given in Fig. 9.

As seen in the blotted bands of Fig. 9, when the genomic DNA of the carboxypeptidase Y mutant strain was treated with restriction enzyme *EcoRI*, a *LEU2* gene was inserted into a *PRC1* fragment 0.65 kb long, to give a fused DNA fragment 1.85 kb long. Where the genomic DNA of the protease mutant strain was treated with
5 restriction enzyme *EcoRV*, a single band corresponding to a size of 10 kb was detected because the *EcoRV* recognition site was removed in the course of replacing the *LEU2* gene for a 1.1 kb *EcoRV* fragment of the *PEP4* gene. Where the genomic DNA of the carboxypeptidase α mutant was cut with restriction enzyme *XhoI*, the *URA3* gene was inserted into a 3.5 kb fragment of the *KEX1* gene to give a fused DNA fragment 4 kb
10 long. On the other hand, this extended DNA fragment was reduced to 2.5 kb as the *URA3* gene was removed in the pop-out strain. Therefore, these results demonstrate that gene disruption was generated on the *PRC1* and *PEP4* genes by the *LEU2* gene of *Hansenula polymorpha* and on the *KEX* gene by the *URA3* gene of *Hansenula polymorpha*.

15 Third step: Analysis of hEGF Secreted From Mutant Strains

For the analysis of the hEGF secreted from the mutants to YP-methanol media (yeast extract 1%, peptone 2%, methanol 2%), the cultures were subjected to centrifugation. The supernatants were allowed to undergo partial purification by use of Sep-Pak cartridge (C18, Waters, Millipore) and analyzed by HPLC. In connection with
20 the partial purification, the Sep-Pak cartridge was activated by the treatment with 10 ml of each of water, methanol, 0.1% trifluoroacetic acid, and 20% acetonitrile/0.1% trifluoroacetic acid and the culture supernatants controlled with 20% acetonitrile and 0.1% trifluoroacetic acid were allowed to pass through the activated Sep-Pak cartridge to absorb the proteins into the cartridge, followed by washing the cartridge with 20%
25 acetonitrile and 0.1% trifluoroacetic acid to take off impurities. The hEGF absorbed was eluted three times with 1 mL of 50 % acetonitrile and 0.1 % trifluoroacetic acid. The eluates containing hEGF were concentrated by freeze-drying.

The samples partially purified were analyzed through reverse phase HPLC (Beckman Model 126 System) using 4.6x250 mm, 5 μ m-C4 column (Vydac) for
30 separating the samples. The mobile phase was moved at a flow rate of 0.8 mL/min

while the concentration was increased from 20% acetonitrile, 0.1% trifluoroacetic acid to 60% acetonitrile, 0.1% trifluoroacetic acid for 35 min. Optical density at 215 nm was measured for the knowledge of sample separation. To determine whether the samples separated from HPLC contained hEGF or not, the fractions at each peak were
5 subjected to ELISA. For this, first, the samples each were suitably diluted in an antigen-coating buffer (0.1 M sodium carbonate buffer, pH 9.6) and the dilutions were added at an amount of 100 μ l in each well of a microtiter plate well (Nunc-immunomodule) and reacted at 37 °C for 2 hours. The wells were washed with PBST (phosphate buffered saline + 0.1% Tween 20), after which 100 μ l of PBS containing
10 0.05% gelatin was added in each of the wells and allowed to stand at 37 °C for 30 min. After being washed with PBST, the wells each were added with 100 μ l of an antibody solution which was obtained by diluting a monoclonal antibody against hEGF (UBI #05-109) 10,000 folds in a PBS containing 0.05% gelatin. Antigen-antibody reaction was conducted at 37 °C for 2 hours in the wells which were, then, washed with PBST.
15 Horse radish-conjugated goat anti-mouse IgG (Bio-Rad) was diluted 3,000 folds in a PBS solution containing 0.05% gelatin, added at an amount of 100 μ l per well and reacted at 37 °C for 1 hour. The wells were washed again with PBST before a coloring reaction. For coloration, a TMB substrate kit (Pierce) was used as a peroxidase substrate. This substrate was mixed at a ratio of 1:1 with a 0.02% solution of peroxide
20 in a mixture of 0.04% TMB (3,3',5,5'-tetramethyl benzidine) and citric acid buffer and added at an amount of 100 μ l per well. After 15 min, 100 μ l of 2M sulfuric acid stopped the enzyme-substrate reaction in each well. After completion of the color reaction, color quantitative analysis was achieved by measuring the absorbance at 450 nm in a 96-well plate autoreader (THERMO max, Molecular Devices, USA). As a
25 control, recombinant hEGF (UBI #01-107) was used in the amount range from 0.25 to 5 ng/well. As a result of the quantitative analysis, the expressed hEGF was detected in two fractions.

These fractions were freeze-dried for qualitative analysis. These two types of hEGF were analyzed for N-terminal amino acid sequence and molecular weight in the
30 Korea Basic Science Institute. From two peaks, hEGF activity was detected. Of them, the relatively hydrophilic peak was found to have a molecular weight of 6,205 as

measured by MALDI-Mass analysis. Therefore, it was a complete hEGF consisting of 53 amino acid residues. On the other hand, the hEGF of the relatively hydrophobic peak, eluted at a higher acetonitrile concentration, was measured to be 6,053 in molecular weight with 52 amino acid residues. Amino acid sequencing analysis read a sequence of Asn-Ser-Asp-Ser-Glu- in the N-terminal region of both the two types of hEGF, revealing that both hEGF molecules are separated accurately from the signal peptide by KEX2. Therefore, the hEGF consisting of 52 amino acid residues resulted from the separation of one amino acid residue from the C-terminal of the whole hEGF. That is, since the whole hEGF has a sequence of -Trp-Trp-Glu-Leu-Arg in its C-terminal region, the separation of the arginine residue from the full length hEGF makes the resulting hEGF of 52 amino acid residues more hydrophobic.

With the information about the HPLC peaks obtained from the above analysis, the hEGF secreted from the *Hansenula polymorpha* UR strain was compared with that secreted from the protease-deficient mutant strain. The total amount of hEGF was lower in the protease A mutant strain than in the UR2 strain, but no great change could be found in the C-terminal decomposition therebetween. On the other hand, a significant carboxypeptidase Y disruption effect was brought about in the carboxypeptidase Y mutant strain. The hEGF which was not degraded in the C-terminal region hEGF, but intact, that is, the hEGF consisting of 53 amino acid residues amounted to 37 % of the hEGF secreted from the UR2 strain, but increased to 57 % in the carboxypeptidase Y mutant strain.

EXAMPLE II

Preparation of Methanol Oxidase (MOX) Gene-Disrupted *Hansenula polymorpha* Mutant Strain

Experiment 1: Construction of pMLT-delta Vector for Disrupting *MOX-TRP3* Gene

The conversion of various yeasts, including *Saccharomyces cerevisiae*, into mutant strains in which particular genes are disrupted, is generally accomplished by

selecting the transformants in which introduced selective marker cassettes are inserted into the genomes through the homologous double crossover at the sites of genes of interest (Rothstein, Meth. Enzymol. 101:202 (1983)). On the other hand, the introduced selective marker cassettes are inserted, for most part, into non-specific sites of the genome of *Hansenula polymorpha* through nonhomologous recombination. Accordingly, only a very low efficiency is imposed on the success in the preparation of a Δ *mox* mutant *Hansenula polymorpha* strain in which a selective marker cassette is inserted into the genome through homologous double crossover at a site of the *MOX* gene to disrupt the *MOX* gene.

10 In order to facilitate a Δ *mox* mutant *Hansenula polymorpha* strain whose *MOX* gene is disrupted, the *MOX* gene and the *TRP3* gene, which is immediately adjacent to the *MOX* gene, were both disrupted on the basis of the previous research result of the present inventors (Agaphonov et al., Yeast 11:1241 (1995)), which discloses that the *TRP* gene (Reid G. A., Nucl. Acids Res. 16, 6236) can be disrupted to the extent of 2% by homologous recombination and an expression cassette carrying a *MOX* promoter and a DNA segment of the *TRP3* gene can be inserted into the genome through the homologous recombination at *MOX* promoter and *TRP3* gene sites to select *TRP*⁺ transformants. To this end, first, a well known vector pSM1 (Agaphonov et al., Yeast 11:1241 (1995)) was digested with *Eco47III/EcoRV* to delete a 2.5 kb DNA fragment comprising a portion of a *MOX* promoter, a whole urokinase gene, and a portion of a *TRP3* gene. Separately, a well known vector YEp13 (Broach et al., Gene 8, 121 (1979)) was digested with *HpaI/SaII* to excise a 2 kb DNA fragment which carried a *LEU2* gene derived from *Saccharomyces*. Replacing the deleted 2.5 kb DNA fragment, the obtained 2 kb DNA fragment was ligated to the linearized pSM1 vector to construct vector pMLT-delta which is capable of disrupting a *MOX* gene and a *TRP* gene at once. This construction scheme is illustrated in Fig. 10. As shown in Fig. 10, pMLT-delta has as a selective maker for *Hansenula polymorpha* a *S. cerevisiae LEU2* gene which is flanked with a portion of a *MOX* promoter and a portion of a *TRP3* gene (*mox(p)::S. cerevisiae LEU2::trp3*).

30 *E. coli* DH5 α harboring the vector pMLT-delta useful to disrupt *MOX-TRP3* genes was deposited in the Korean Collection for Type Culture of Korea Research

Institute of Bioscience and Biotechnology under the Accession No. KCTC 0727BP on Feb. 10, 2000.

Experiment 2: Construction of Novel Δmox Mutant DLT2 and Characterization

As a mother strain for the preparation of a *MOX-TRP3* gene-disrupted mutant, there was employed DL1-L (*leu2*), a leu-auxotrophic *Hansenula polymorpha* DL-1 (ATCC 26012)-derived mutant.

The vector pMLT-delta obtained above was cut with restriction enzymes *Xho*I and *Sac*I and introduced, according to the Hill method (Hill et al., *Nucl. Acids Res.* 19: 5791(1991)) into *Hansenula polymorpha* DL1-L(*leu2*) which was, then, cultured on a tryptophane-containing minimal solid medium (2% glucose, 0.67% amino acid-deficient yeast base, 20 mg/L tryptophane) to primarily select LEU⁺ transformants. With the aim of selecting a *trp*⁻, *mox*⁻ transformants (Fig. 11) in which the introduced *mox(p)::S. cerevisiae LEU2::trp3* cassette was inserted into the *MOX* promoter and *TRP3* gene site through homologous recombination, an observation was made whether these LEU⁺ transformants could be grown on a tryptophane-deficient medium containing methanol as a sole carbon source. Through the Southern blotting using a *MOX* promoter and a *TRP3* gene fragment as probes, the selected *trp*⁻, *mox*⁻ transformants were investigated as to whether a major part of the *MOX* gene and a portion of the *TRP3* gene on their genome were disrupted. The finally selected mutant was called DLT2 (*leu2 mox trp::LEU2*). Because DLT2 cannot produce methanol oxidase any more owing to the disruption of the *MOX* gene on the genome, its consumption rate of methanol is greatly reduced compared with *MOX* wild type DL1-L's, making it virtually impossible for DLT2 to grow in the medium containing methanol as a sole carbon source, as apparent from the results of Figs. 12A and 12B. In addition, the mutant cannot be grown in tryptophane-deficient media or YPD medium (2% glucose, 2% peptone, 1% yeast extract) on account of *TRP3* gene disruption, as seen in Figs. 12C, 12D and 12E.

This Δmox mutant DLT2 was deposited in the Korean Collection for Type Culture of Korea Research Institute of Bioscience and Biotechnology under the accession No. KCTC 0728BP on Feb. 10, 2000.

Experiment 3: Insertion of Expression Vector Into *MOX* Gene Region of DLT2 and Pop-Out Therefrom

Hansenula polymorpha is transformed mainly through nonhomologous recombination, so that most of the introduced expression vectors are inserted into non-specific sites on the genome. However, in the event that an expression cassette which comprised a *MOX* promoter and a portion of a *TRP3* gene at its opposite ends respectively was introduced into the DLT2 host, which is of Δmox as well as Δtrp , there could be obtained TRP^+ transformants as a result of the homologous recombination at the *MOX* promoter and *TRP3* gene site on the genome. That is, the transformants in which the expression cassette was inserted into the *MOX* gene site (Fig. 13A) could be selected with relative ease.

Furthermore, where the inserted expression vector would be popped out later, the vector pMLT-delta cut with *Xho*I and *Sac*I, which had been used for the preparation of DLT2 in the above experiment 2, was introduced again into the recombinant DLT2 strain to select LEU^+ transformants. Identification as to whether the transformants were of mox^+ , trp^+ phenotype and expressed preexisting recombinant proteins assured the removal of the preexisting recombinant expression vector from the genome through the homologous recombination, as illustrated in Fig. 13B. By this technique, a DLT2 transformant harboring an old expression vector could be returned to its original DLT2, which was thus ready to adopt a new expression vector comprising a *MOX* promoter and a portion of a *TRP3* gene at its *MOX* site.

In addition, a 3.5 kb DNA fragment comprising a *MOX* gene and a *TRP3* gene was obtained by cutting pMOX3616 (KRIBB report BSKG 1050-885-3) with restriction enzymes *Pst*II/*Xba*I and introduced into DLT2 transformants. Of them, the transformant that rapidly grew on a synthetic medium supplemented with methanol and leucine was selected. That is, the preexisting expression vector inserted into the *MOX* gene was popped out to revive the *MOX* gene, which led to the conversion of the DLT2 transformant into a MOX^+ strain, as illustrated in Fig. 13C.

Consequently, after DLT2 transformants are mutated, the previously inserted expression vectors can be removed and replaced with new expression vectors on the

host genomes. Alternatively, mutants of desired phenotypes can be prepared under the background of MOX^+ wild type. Therefore, the pop-out technique for expression vectors inserted into host genomes allows previously developed mutant strains to be used as hosts for producing various recombinant proteins.

5 Experiment 4: Comparison of Recombinant Protein Expression Efficiency Between MOX Wild Type and Δmox Mutant

To compare the recombinant protein expression efficiency of a MOX wild type with that of a Δmox mutant strain, DL1-L was used as the MOX wild type while the DLT2, prepared in the above experiment 2, was selected for the mutant strain. The recombinant protein of interest was human urinary plasminogen kinase (u-PA), simply called urokinase. Into the MOX gene site of the DLT2 strain (*leu2 mox-trp3::ScLEU2*), vector pSM1 (Agaphonov et al., Yeast 11: 1241 (1995)) carrying a u-PA expression cassette in which a u-PA gene is linked to a MOX promoter, was introduced to obtain a Δmox transformant which could express u-PA. On the other hand, a MOX transformant capable of expressing u-PA was prepared by introducing vector pKSM8 (Agaphonov et al., unpublished result), which carries the same u-PA expression cassette, but uses *HLEU2-d* (Agaphonov et al., Yeast 15: 541 (1999)) as a selective marker, into DL1-L(*leu2*) and selecting a LEU^+ transformant.

After being cultured in YPD medium (yeast extract 1%, bacto-peptone 2%, dextrose 2%) for 18 hours, the transformants selected were inoculated into IM medium (yeast extract 1%, bacto-peptone 3%, methanol 2%) at an amount of 17 % and cultured for 70 hours with shaking. The u-PA secreted into cell cultures was analyzed for activity with the aid of fibrin plates in accordance with the Astrup method (Astrup et al., Arch. Biochem. Biophys. 40: 346 (1952)). Because the Δmox transformant grows at a lower rate in IM medium containing methanol as a main carbon source than does the MOX transformant, the u-PA activity of cell cultures obtained after 70 hours of the cultivation was calibrated against the total amount of cell proteins and expressed as IU per mg of total cell protein (IU/mg of t.c.p.). The results are given in Table 2, below. As apparent from the data of Table 2, the u-PA expression efficiency of the Δmox

transformant is four times as much as that of the *MOX* transformant, demonstrating that the DLT2 strain is excellent as a u-PA producing host.

TABLE 2

Expression Efficiency of Urokinase in *Hansenula polymorpha* *MOX* Wild Type (DL1-L) and Δmox Mutant (DLT2) After Shake Culturing in Flask

#	<i>MOX</i> status	U-PA activity (IU/ml)	Specific Activity (IU/mg of t.c.p.)	Mean Value (IU/mg of t.c.p.)
1	<i>MOX</i>	19	6.8	7.6
2		25	9.2	
3		22	6.9	
4	Δmox	28	28	29.6
5		18	23	
6		29	36	
7		25	34	
8		26	27	

15 Experiment 5: Production of Recombinant Albumin in Δmox Mutant DLT2

Using human serum albumin(HSA), comparison was also conducted for the recombinant expression efficiency between a *MOX* wild type and a Δmox transformant. For this, there was first constructed a recombinant albumin expression cassette in which a gene coding for human serum albumin was inserted between a *MOX* promoter and a *TRP3* gene fragment. By introducing the albumin cassette into a *MOX* gene site of the Δmox mutant DLT2, a transformant DLT2/HSA was prepared (Kang et al., unpublished) and deposited in the Korean Collection for Type Culture of the Korea Research Institute of Bioscience and Biotechnology (KRIBB) under the accession number KCTC 0740BP on March 2, 2000. As a transformant in which the albumin expression cassette was

introduced into a *MOX* gene site of the *MOX* wild type, there was employed DL1-L/T7 which had been prepared in previous research (Korean Pat. Appl'n No. 133190). These transformants were seed-cultured for 16-20 hours in YPG medium (yeast extract 1%, bacto-peptone 2%, glycerol 2%) and then, cultured for 72 hours with shaking in 250 ml baffled flasks containing expression-inducing YPM medium (yeast extract 1%, bacto-peptone 2%, methanol 2%). As for albumin quantification, the albumin secreted into the cell cultures was measured by Western blotting (Kang et al., J. Microbiol. Biotechnol. 8, 42 (1998)) while the intensity of appearing bands was read with the aid of a densitometer (Bio-Rad, Model GS-700).

10 Because the Δmox mutant DLT2 hardly grows in YPM medium which use methanol as a sole carbon source as described in the above experiments 2 and 4, the transformants were cultured in two steps for comparison. In detail, the transformants were first cultured in 50 ml of YPG medium supplemented with glycerol and then, the total cells harvested by centrifugation were inoculated at a high density into 25 ml of
15 YPM medium. Under the culturing condition of such methanol medium, the inocula did not grow further, but the albumin production continued to be conducted by virtue of the presence of the *MOX* promoter. As for the Δmox transformant DL1-L/HSA, it produced albumin at an amount of about 120 mg/L when being cultured in 2% methanol-containing YPM medium in flask, as shown in Fig. 14. This was about twice greater
20 than the albumin amount produced when the *MOX* transformant DL1-L/T7 was cultured at a high density, indicating the possibility that the Δmox strain might be more productive of recombinant proteins than might the *MOX* wild type even when being cultured at a high density in a large-scale fermentation bath for the mass production of recombinant proteins. Particularly, when the methanol concentration was lowered to
25 0.5%, the albumin production of DLT2/HSA was increased rather than decreased, whereas DL1-L/T7 was greatly degraded in albumin expression efficiency because the methanol was rapidly consumed as a carbon source. Therefore, the Δmox strain has another advance over the *MOX* wild type in that recombinant proteins can be obtained at high efficiency without continuously feeding methanol and the fermentation process is
30 relatively simple.

Experiment 6: Use of the pop-out technique to development of novel mutant strains as hosts for general use in producing various recombinant proteins

The plasmid shuffling technique to facilitate the removal of the expression vector from the host cell has been well developed in the traditional yeast *S. cerevisiae*, where most expression cassettes were retained in an episomal vector capable of extrachromosomal replication (Boeke et al., *Meth. Enzymol.* 154, 164, 1987). The technique provides the *S. cerevisiae* expression system with a powerful means to allow mutant strains, derived from a parental recombinant strain, to be developed as useful host strains for general in producing various heterologous proteins. A recombinant *S. cerevisiae*, strain expressing a reporter protein, which can be easily analyzed, can be mutagenized and screened for the desired phenotype such as super-secretion. After removal of the pre-existent expression vector from the obtained mutants strain of *S. cerevisiae*, another expression vector can be introduced into the mutants strains to express other recombinant proteins. By contrast, this kind of procedure has been unable to be carried out in the *H. polymorpha* system mainly due to the non-specific integration of expression vector into the host chromosomal DNA.

However, the present invention of DLT2 provides the *H. polymorpha* system with the pop-out technique in which a recombinant protein expression cassette integrated into the host chromosome can be efficiently popped out therefrom, as shown in the above experiment 3. The activity of U-PA can be also easily analyzed by the plate assay. Therefore, using the recombinant DLT2/u-PA (leu2 mox-trp3::u-PA) expressing u-PA as the parental strain, which was constructed in the above experiment 4, we carried out the experiment to isolate super-secretion mutant strains therefrom and to develop the obtained mutant strains as the general host strains for the production of other recombinant proteins (Fig. 15). To obtain mutant strains with the increased secretion capacity, the recombinant DLT2/u-PA was undergone with the mutagenesis caused by the chemical mutagen, ethyl methane sulfonate (EMS). After incubation in 3.5% EMS solution for 30 min and subsequent neutralization with 6 % thiosulfate nitrium, the mutagenized cells were plated into the fibrin plate (Agaphonov et al., *Yeast* 15, 541, 1999) and compared with the parental strain DLT2/u-PA for the secretion

capacity of u-PA. Among several super-secretion mutants showing at least more than two-fold improved secretion, a mutant named DLT-90-20/u-PA (leu2 mox-trp3::u-PA opu90-20) with the three-fold improvement in the u-PA secretion was chosen to be developed as the general host strain for the production of other heterologous proteins.

5 As described in the Figure 13B of the above experiment 3, the XhoI/SacI truncated pMLT-delta was reintroduced into the DLT-90-20/u-PA mutant strain for the selection of LEU+ transformants. Subsequently, the mox-, trp- transformants were selected therefrom and the pop-out of the u-PA expression cassette was confirmed on the fibrin plate. In this procedure, the DLT90-20 mutant strain was converted to have the MOX-

10 TRP3 genes disrupted with the ScLEU2 cassette like the original strain DLT2. To exploit the obtained super-secretion mutant DLT90-20 (leu2 mox-trp3::ScLEU2 opu90-20) as the host for the production of other recombinant proteins, the HSA expression cassette was inserted into the MOX gene site of DLT90-20 according to the procedure explained in the above experiment 5. The resultant recombinant strain DLT90-20/HSA

15 was compared with the DLT2/HSA, which was constructed in the above experiment 5, for the production capacity of HSA. The DLT90-20/HSA strain showed 150% improvement in the HSA secretion than the DLT2/HSA, indicating that the super-secretion mutant 90-20 is also useful for the production of HSA. The present result demonstrates that another major advantage of the DLT2 strain in the present invention

20 over the previous host strains of *H. polymorpha* is the feasibility of pop-out technique, which allows the obtained novel mutant strains to be utilized as a general host strain for the production of various recombinant proteins in the *H. polymorpha* expression system.

INDUSTRIAL APPLICABILITY

25 As described hereinbefore, the present invention can bring about a great improvement in the expression efficiency of the recombinant protein producing system through *Hansenula polymorpha* as well as in the simplification of the fermentation procedure. In addition, the present invention provides a technique by which *Hansenula polymorpha* is allowed to be used as a general host for producing various proteins.

30 The *Hansenula polymorpha* carboxypeptidase Y mutant strain in which the gene

PRC1 coding for carboxypeptidase Y is disrupted, is found to be lower in the carboxyl terminal degradation of an exogenous protein, e.g., hEGF by as much as 40% than the wild type. The *Hansenula polymorpha* strain in which the gene *KEX1* coding for carboxypeptidase α is disrupted in addition to the gene *PRC1* coding for

5 carboxypeptidase Y, is further decreased in the carboxyl terminal degradation of exogenous proteins. As for the *Hansenula polymorpha* protease A mutant strain in which the gene *PEP4* coding for protease A is disrupted, it does not exhibit a decrease in the carboxy terminal degradation of hEGF, but is greatly decreased in degrading other exogenous proteins at their carboxyl terminals. In addition, the *Hansenula*

10 *polymorpha* Δmox mutant, which is transformed with the vector pMLT-delta useful to disrupt *MOX* and *TRP3* genes, can play an excellent role as a host in producing various proteins without continuous feeding of methanol because the expression cassette enables the expression of recombinant proteins to be induced at high efficiency in a medium containing a low concentration of methanol. Furthermore, the expression cassette

15 inserted into a *MOX* gene site of the genome of the Δmox mutant strain can be popped out effectively. Thence, after mutation is caused in a Δmox transformant, a new expression vector can be re-introduced replacing the previously inserted expression vector, or mutants of desired phenotypes can be prepared under the background of *MOX*⁺ wild type. Therefore, the mutants previously developed can fulfill themselves as

20 hosts for general use in producing various proteins.

The present invention has been described in an illustrative manner, and it is to be understood that the terminology used is intended to be in the nature of description rather than of limitation. Many modifications and variations of the present invention are possible in light of the above teachings. Therefore, it is to be understood that within the

25 scope of the appended claims, the invention may be practiced otherwise than as specifically described.

PCT

34

YL000304PCT

Original (for SUBMISSION) - printed on 04.03.2000 01:21:07 PM

0-1	Form - PCT/RO/134 (EASY) Indications Relating to Deposited Microorganism(s) or Other Biological Material (PCT Rule 13bis)	
0-1-1	Prepared using	PCT-EASY Version 2.90 (updated 15.12.1999)
0-2	International Application No.	PCT/ER 00/00173
0-3	Applicant's or agent's file reference	YL000304PCT
1	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
1-1	page	11
1-2	line	14-18
1-3	Identification of Deposit	
1-3-1	Name of depositary institution	Korean Collection for Type Cultures
1-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
1-3-3	Date of deposit	10 February 2000 (10.02.2000)
1-3-4	Accession Number	KCTC 0727BP
1-4	Additional Indications	NONE
1-5	Designated States for Which Indications are Made	all designated States
1-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
2	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
2-1	page	11
2-2	line	18-22
2-3	Identification of Deposit	
2-3-1	Name of depositary institution	Korean Collection for Type Cultures
2-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
2-3-3	Date of deposit	10 February 2000 (10.02.2000)
2-3-4	Accession Number	KCTC 0728BP
2-4	Additional Indications	NONE
2-5	Designated States for Which Indications are Made	all designated States
2-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE

PCT

35

YL000304PCT

Original (for SUBMISSION) - printed on 04.03.2000 01:21:07 PM

3	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
3-1	page	14
3-2	line	9-12
3-3	Identification of Deposit	
3-3-1	Name of depositary institution	Korean Collection for Type Cultures
3-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
3-3-3	Date of deposit	18 February 2000 (18.02.2000)
3-3-4	Accession Number	KCTC 0732BP
3-4	Additional Indications	NONE
3-5	Designated States for Which Indications are Made	all designated States
3-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
4	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
4-1	page	15
4-2	line	10-14
4-3	Identification of Deposit	
4-3-1	Name of depositary institution	Korean Collection for Type Cultures
4-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
4-3-3	Date of deposit	18 February 2000 (18.02.2000)
4-3-4	Accession Number	KCTC 0733BP
4-4	Additional Indications	NONE
4-5	Designated States for Which Indications are Made	all designated States
4-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
5	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
5-1	page	16
5-2	line	11-15
5-3	Identification of Deposit	
5-3-1	Name of depositary institution	Korean Collection for Type Cultures
5-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
5-3-3	Date of deposit	18 February 2000 (18.02.2000)
5-3-4	Accession Number	KCTC 0731BP
5-4	Additional Indications	NONE

PCT

YL000304PCT

Original (for SUBMISSION) - printed on 04.03.2000 01:21:07 PM

5-5	Designated States for Which Indications are Made	all designated States
5-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
6	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
6-1	page	18
6-2	line	27-30
6-3	Identification of Deposit	
6-3-1	Name of depositary institution	Korean Collection for Type Cultures
6-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
6-3-3	Date of deposit	18 February 2000 (18.02.2000)
6-3-4	Accession Number	KCTC 0736BP
6-4	Additional Indications	NONE
6-5	Designated States for Which Indications are Made	all designated States
6-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
7	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
7-1	page	20
7-2	line	24-29
7-3	Identification of Deposit	
7-3-1	Name of depositary institution	Korean Collection for Type Cultures
7-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
7-3-3	Date of deposit	18 February 2000 (18.02.2000)
7-3-4	Accession Number	KCTC 0735BP
7-4	Additional Indications	NONE
7-5	Designated States for Which Indications are Made	all designated States
7-6	Separate Furnishing of Indications These indications will be submitted to the International Bureau later	NONE
8	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
8-1	page	20
8-2	line	24-29

PCT

YL000304PCT

Original (for SUBMISSION) - printed on 04.03.2000 01:21:07 PM

8-3	Identification of Deposit	
8-3-1	Name of depositary institution	Korean Collection for Type Cultures
8-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
8-3-3	Date of deposit	18 February 2000 (18.02.2000)
8-3-4	Accession Number	KCTC 0734BP
8-4	Additional Indications	NONE
8-5	Designated States for Which Indications are Made	all designated States
8-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	
9	The indications made below relate to the deposited microorganism(s) or other biological material referred to in the description on:	
9-1	page	29
9-2	line	20-24
9-3	Identification of Deposit	
9-3-1	Name of depositary institution	Korean Collection for Type Cultures
9-3-2	Address of depositary institution	52, Oun-dong, Yusong-Ku, Taejon 305-333, Republic of Korea
9-3-3	Date of deposit	02 March 2000 (02.03.2000)
9-3-4	Accession Number	KCTC 0740BP
9-4	Additional Indications	NONE
9-5	Designated States for Which Indications are Made	all designated States
9-6	Separate Furnishing of Indications	NONE
	These indications will be submitted to the International Bureau later	

FOR RECEIVING OFFICE USE ONLY

0-4	This form was received with the international application: (yes or no)	
0-4-1	Authorized officer	

FOR INTERNATIONAL BUREAU USE ONLY

0-5	This form was received by the International Bureau on:	
0-5-1	Authorized officer	

CLAIMS

1. A *PRC1* gene derived from *Hansenula polymorpha* DL1 (ATCC 26012), having the base sequence listed in Sequence 1, which codes for carboxypeptidase Y.
2. A vector pHYL, which is constructed by inserting a *Hansenula polymorpha* *LEU2* gene into a plasmid pHDY2 (KCTC 0732BP) carrying the *PRC1* gene of Sequence 1 in such a way that the *PRC1* gene is disrupted.
3. A vector pHYUZ, which is constructed by inserting a *Hansenula polymorpha* *URA3* gene pop-out cassette into a plasmid pHDY2 carrying the *PRC1* gene of Sequence 1 in such a way that the *PRC1* gene is disrupted.
- 10 4. A carboxypeptidase Y mutant strain, into which a *Hansenula polymorpha* UR2 strain is transformed with the vector pHYL of claim 2.
5. A carboxypeptidase Y mutant strain, *Hansenula polymorpha* DL1/ Δ cpy(KCTC 0735 BP), into which a *Hansenula polymorpha* DL1 strain is transformed with the vector pHYUZ of claim 3.
- 15 6. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the carboxypeptidase Y mutant strain of claim 4 and the cell is cultured in a culture medium.
7. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the carboxypeptidase Y mutant strain of claim 5
20 and the cell is cultured in a culture medium.
8. A recombinant protein, which is produced by the process of claim 6 or 7.
9. A *PEP4* gene derived from *Hansenula polymorpha* DL1 (ATCC 26012),

having the base sequence listed in Sequence 2, which codes for protease A.

10. A vector pHPL, which is constructed by inserting a *Hansenula polymorpha* *LEU2* gene into a plasmid pHDP4 (KCTC 0733BP) carrying the *PEP4* gene of Sequence 2 in such a way that the *PEP4* gene is disrupted.

5 11. A vector pHPUZ, which is constructed by inserting a *Hansenula polymorpha* *URA3* gene pop-out cassette into a plasmid pHDP4 carrying the *PEP4* gene of Sequence 2 in such a way that the *PEP4* gene is disrupted.

12. A protease A mutant strain, into which a *Hansenula polymorpha* UR2 strain is transformed with the vector pHPL of claim 10.

10 13. A protease A mutant strain, *Hansenula polymorpha* DL1/ Δ pep4(KCTC 0734 BP), into which a *Hansenula polymorpha* DL1 strain is transformed with the vector pHPUZ of claim 11.

14. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the protease A mutant strain of claim 12 and the
15 cell is cultured in a culture medium.

15. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the protease A mutant strain of claim 13 and the cell is cultured in a culture medium.

16. A recombinant protein, which is produced by the process of claim 14 or 16.

20 17. A *KEX1* gene derived from *Hansenula polymorpha* DL1 (ATCC 26012), having the base sequence listed in Sequence 3, which codes for carboxypeptidase α .

18. A vector pKUZ, which is constructed by inserting a *Hansenula polymorpha*

URA3 gene pop-out cassette into a plasmid pKH3.9 carrying the *KEX1* gene of Sequence 3 in such a way that the *KEX1* gene is disrupted.

19. A carboxypeptidase α mutant strain, *Hansenula polymorpha* DL1/ Δ kex1(KCTC 0736 BP), into which a *Hansenula polymorpha* DL1 strain is
5 transformed with the vector pKUZ of claim 18.

20. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the carboxypeptidase α mutant strain of claim 19 and the cell is cultured in a culture medium.

21. A recombinant protein, which is produced by the process of claim 20.

10 22. A carboxypeptidase Y/protease A mutant strain, into which a *Hansenula polymorpha* DL1 strain is transformed with the vector pHYUZ of claim 3 and the vector pHPUZ of claim 11.

23. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the carboxypeptidase Y/protease A mutant strain of
15 claim 22 and the cell is cultured in a culture medium.

24. A recombinant protein, which is produced by the process of claim 23.

25. A carboxypeptidase Y/carboxypeptidase α mutant strain, into which a *Hansenula polymorpha* DL1 strain is transformed with the vector pHYUZ of claim 3 and the vector pKUZ of claim 20.

20 26. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the carboxypeptidase Y/carboxypeptidase α mutant strain of claim 25 and the cell is cultured in a culture medium.

27. A recombinant protein, which is produced by the process of claim 26.
28. A recombinant protein in accordance with claim 27, wherein the recombinant protein is human epidermal growth factor (hEGF).
29. A protease A/carboxypeptidase α mutant strain, into which a *Hansenula polymorpha* DL1 strain is transformed with the vector pHPUZ of claim 11 and the vector pKUZ of claim 18.
30. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the protease A/carboxypeptidase α mutant strain of claim 29 and the cell is cultured in a culture medium.
31. A recombinant protein, which is produced by the process of claim 30.
32. A carboxypeptidase Y/protease A/carboxypeptidase α mutant strain, into which a *Hansenula polymorpha* DL1 strain is transformed with the vector pHYUZ of claim 3, the vector pHPUZ of claim 11, and the vector pKUZ of claim 18.
33. A process for producing a recombinant protein, wherein a gene coding for an exogenous protein is introduced into the carboxypeptidase Y/protease A/carboxypeptidase α mutant strain of claim 32 and the cell is cultured in a culture medium.
34. A recombinant protein, which is produced by the process of claim 33.
35. A vector pMLT-delta (KCTC 0727BP), which carries as a selective marker for *Hansenula polymorpha* a *Sacchromyces cerevisiae* *LEU2* inserted between a portion of a *MOX* promoter and a DNA fragment comprising a portion of a *TRP3* gene (mox(p)::*S.cerevisiae* *LEU::trp3*).

36. A *Hansenula polymorpha* Δ *mox* mutant strain, which is prepared by introducing the vector pMLT-delta of claim 35 into *Hansenula polymorpha* in such a way that the *MOX-TRP3* gene of *Hansenula polymorpha* is disrupted.

37. A *Hansenula polymorpha* Δ *mox* mutant strain in accordance with claim 36,
5 wherein the *Hansenula polymorpha* is a *Hansenula polymorpha* DL1 strain.

38. A *Hansenula polymorpha* Δ *mox* mutant strain DLT2 (KCTC 0728BP), which is prepared by introducing the vector pMLT-delta of claim 35 into *Hansenula polymorpha* DL1-L in such a way that the *MOX-TRP3* gene of *Hansenula polymorpha* is disrupted.

10 39. A process for producing a recombinant protein, wherein the *Hansenula polymorpha* Δ *mox* mutant strain of any of claims 36 to 38 is transformed with an expression cassette and cultured in a methanol medium, serving as a recombinant protein expression host, said expression cassette comprising a promoter whose expression is induced by methanol.



15 40. A process in accordance with claim 39, wherein the *Hansenula polymorpha* Δ *mox* mutant strain is first cultured to a high concentration in a medium containing glycerol as a carbon source and then, cultured in a medium containing methanol as a carbon source.

41. A recombinant protein, which is produced by the process of claim 39 or 40.


20 42. A process for popping-out an expression cassette integrated into the *MOX* gene site of the Δ *mox* strain DLT2.

43. A process for developing novel mutant strains derived from a recombinant DLT2 strain, which is prepared in accordance with claim 38, into a host for general use in producing various recombinant proteins using the pop-out technique of claim 42.


1/13

FIG. 1**FIG. 2**


2/13

FIG. 3


3/13

FIG. 4


4/13

FIG. 5

5/13


FIG. 6

6/13


FIG. 7

7/13

FIG. 8



8/13

FIG. 9

A. Lane 1 : *H. polymorpha* UR2/*EcoRV*
 Lane 2 : *pep4* mutant/*EcoRV*
 Lane 3 : DIG- λ /*HindIII* size marker
 probe : DIG labeled pHDP4/*SacI*/*HindIII* 2kb fragment

B. Lane 1 : *H. polymorpha* UR2/*EcoRI*
 Lane 2 : *prc1* mutant/*EcoRI*
 Lane 3 : DIG- λ /*HindIII* size marker
 probe : DIG labeled pHDY2/*EcoRI* 1.5kb fragment

C. Lane 1,5 :DIG-1 kb size marker
 Lane 2 : *H. polymorpha* DL1/*XhoI*
 Lane 3 : *kex1* mutant/*XhoI*
 Lane 4 : URA3 gene pop-out/*XhoI*
 probe : DIG labeled pKH4.5/*XhoI* 3.5kb fragment

9/13

FIG. 10






FIG. 11



10/13

FIG. 12


A. 2% Glucose + 0.67% YNB
+ LEU + TRP



B. 0.5% Methanol + 0.67% YNB
+ LEU + TRP





C. 2% Glucose + 0.67% YNB
+ LEU





D. 2% Glucose + 0.67% YNB
+ TRP





E. 2% Glucose + 2% Peptone
+ 1% Yeast extract




11/13

FIG. 13a**FIG. 13b**

12/13

FIG. 13c**FIG. 14**

13/13

FIG. 15

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 September 2000 (08.09.2000)

PCT

(10) International Publication Number
WO 00/52133 A3

(51) International Patent Classification⁷: C12N 15/63,
15/57, 15/81, 15/81

(21) International Application Number: PCT/KR00/00173

(22) International Filing Date: 4 March 2000 (04.03.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1999/7177 4 March 1999 (04.03.1999) KR
2000/10743 3 March 2000 (03.03.2000) KR

(71) Applicants (for all designated States except US): KOREA
RESEARCH INSTITUTE OF BIOSCIENCE AND
BIOTECHNOLOGY [KR/KR]; 52, Oun-Dong, Yu-
song-Ku, Taejon 305-333 (KR). DONG KOOK PHAR-
MACEUTICAL CO. [KR/KR]; 997-8, Daechi-Dong,
Kangnam-Ku, Seoul 135-280 (KR).

(72) Inventors; and

(75) Inventors/Applicants (for US only): RHEE, Sangki
[KR/KR]; GA-101, Geukdong Villa, Gwangjang-Dong,
Gwangjin-K, u Seoul 143-210 (KR). CHOI, Euisung
[KR/KR]; 102-507, Dasol Apt. #395-3, Goong-Dong,
Yusong-Ku, Taejon 305-335 (KR). KANG, Hyunah
[KR/KR]; 102-1202, Hana Apt. Shinsung-Dong, Yu-
song-Ku, Taejon 305-345 (KR). SOHN, Junghoon
[KR/KR]; 103-506, Nuri Apt. Wolpyung-Dong, Seo-Ku,
Taejon 302-280 (KR). BAE, Junghoon [KR/KR]; 302,
#120-2, Shinsung-Dong, Yusong-Ku, Taejon 305-345
(KR). KIM, Moowoong [KR/KR]; 201, Art Villa,

#101-2, Oun-Dong, Yusong-Ku, Taejon 305-333 (KR).
AGAPHONOV, Michael [RU/RU]; Institute of Exper-
imental Cardiology, Cardiology Research Center, 3RD
Cherepkovskaya Street 15A, Moscow, 121552 (RU).
KIM, Myungkuk [KR/KR]; 102-901, Doonchonyeok
Chunggu Apt, #419-1, Sungnae-3-Dong, Kangdong-Ku,
Seoul 134-033 (KR).

(74) Agent: LEE, Duckro; 2nd floor, Yeil Building, 700-19,
Yorksam-Dong Kangnam-Ku, Seoul 135-080 (KR).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— With international search report.

(88) Date of publication of the international search report:
28 December 2000

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 00/52133 A3

(54) Title: *HANSENULA POLYMORPHA* MUTANTS AND PROCESS FOR THE PREPARATION OF RECOMBINANT PRO-
TEINS USING THE SAME

(57) Abstract: Disclosed are *Hansenula polymorpha* mutants useful as host cells through which various proteins can be produced as being intact at high yield and a process for preparing recombinant proteins using the host cells. Using various vectors, *Hansenula polymorpha* is made to be a mutant which is deprived of methanol assimilating ability and incapable of utilizing methanol as a carbon source. This *Hansenula polymorpha* mutant is used as a high yield host to produce recombinant proteins without continuous feeding of methanol, with the aid of an expression cassette carrying a promoter capable of inducing the expression at a low concentration of methanol. Further, the mutant is also lacking in carboxypeptidase Y, protease Y and/or carboxypeptidase α activity, so the recombinant protein of interest is not degraded at its carboxyl terminal when being expressed in the cell. Thus, intact recombinant protein can be obtained. Also, there is disclosed a pop-out technique in which a recombinant protein expression cassette is inserted into a *MOX* gene site of the mutant and is allowed to pop out therefrom, thereby utilizing the mutant as a host for general use in producing various proteins of interest.

INTERNATIONAL SEARCH REPORT

International application No
PCT KR00/00173

A. CLASSIFICATION OF SUBJECT MATTER IPC7 C12N 15/63, C12N 15/57, C12N 15/81, C12N 15/81 According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched C12N Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) NCBI pubmed, Entrez, Blast -"yeast, KEX1, PEP4, PRC1"		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Eur J. Biochem. Dec 1994, vol 226, No 2, pages 341-53	17-34
A	Eur J. Biochem Jan. 1994, vol 219, No 1-2, pages 647-52	17-34
A	J Biol Chem Jan. 1993, vol 268, No 1, pages 534-40	17-34
A, P	Yeast May 1999, vol 15, No 7, pages 563-72	17-34
A	Yeast Jan 1996, vol 12, No 1, pages 31-40	1-8
A	Biomed Biochim Acta, 1991, vol 50, No 4-6, pages 711-6	1-8
A, P	Yeast Feb. 2000, vol. 1, No.3, pages 207-17	9-16
A	J Biol Chem Sep 1996, vol. 271, No. 36, pages 21944-9	9-16
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 21 AUGUST 2000 (21.08.2000)		Date of mailing of the international search report 28 AUGUST 2000 (28.08.2000)
Name and mailing address of the ISA, KR Korean Industrial Property Office Government Complex-Taejeon, Dunsan-dong, So-ku, Taejeon Metropolitan City 302-701, Republic of Korea Facsimile No. 82-42-472-7140		Authorized officer LIM, Hea Joon Telephone No. 82-42-481-5590

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.